INmune Bio, Inc. (INMB)

NASDAQ: INMB · Real-Time Price · USD
7.64
-0.43 (-5.33%)
Apr 3, 2025, 10:15 AM EDT - Market open
-5.33%
Market Cap 175.19M
Revenue (ttm) 14,000
Net Income (ttm) -42.08M
Shares Out 22.93M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,566
Open 7.71
Previous Close 8.07
Day's Range 7.48 - 7.86
52-Week Range 4.32 - 12.72
Beta 1.94
Analysts Strong Buy
Price Target 24.33 (+218.46%)
Earnings Date Mar 27, 2025

About INMB

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2019
Employees 17
Stock Exchange NASDAQ
Ticker Symbol INMB
Full Company Profile

Financial Performance

In 2024, INmune Bio's revenue was $14,000, a decrease of -90.97% compared to the previous year's $155,000. Losses were -$42.08 million, 40.2% more than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for INMB stock is "Strong Buy." The 12-month stock price forecast is $24.33, which is an increase of 218.46% from the latest price.

Price Target
$24.33
(218.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer ...

6 days ago - Seeking Alpha

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness...

6 days ago - GlobeNewsWire

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffe...

Other symbols: PNWPRI
12 days ago - Seeking Alpha

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billio...

15 days ago - Seeking Alpha

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) ...

7 weeks ago - GlobeNewsWire

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc.   (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that ha...

7 weeks ago - GlobeNewsWire

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial fo...

3 months ago - Seeking Alpha

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows pot...

3 months ago - Seeking Alpha

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

HOUSTON & BOCA RATON, Fla.--(BUSINESS WIRE)--OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's ...

4 months ago - Business Wire

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neurosci...

5 months ago - Seeking Alpha

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

5 months ago - GlobeNewsWire

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET.

5 months ago - GlobeNewsWire

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell

5 months ago - GlobeNewsWire

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”),  a clinical-stage inf...

5 months ago - GlobeNewsWire

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --    INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neur...

6 months ago - GlobeNewsWire

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout ...

6 months ago - Seeking Alpha

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK)...

6 months ago - GlobeNewsWire

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional ...

7 months ago - GlobeNewsWire

INmune Bio Announces $13.0 Million Registered Direct Offering

Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treat...

7 months ago - GlobeNewsWire

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that ha...

7 months ago - GlobeNewsWire

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

INmune Bio, Inc. (NASDAQ:INMB) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscien...

8 months ago - Seeking Alpha

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and imm...

8 months ago - GlobeNewsWire

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc.  (NASDAQ: INMB) ...

8 months ago - GlobeNewsWire

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immu...

9 months ago - GlobeNewsWire

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics

9 months ago - GlobeNewsWire